| galantamine |
beta-secretase1 (BACE1) |
44%
decrease in BACE1 level/0.3 μM |
(74) |
| donepezil |
beta-secretase1
(BACE1) |
IC50 = 3.2 μM |
(75) |
| donepezil |
nitric oxide synthase,
brain (NOS1) |
increase expression of NOS1/5 mg/kg in vivo |
(76) |
| donepezil |
glycogen synthase kinase-3 beta (GSK3B) |
decrease 77% in vivo/(1 mg/kg) |
(77) |
| memantine |
monoamine oxidase
type B (MAO-B) |
inhibition of 64%/1 mM |
(78) |
| memantine |
Adenosine receptor
A2a (AA2AR) |
increase 43% in vivo (25 mg/kg) |
(79) |
| memantine |
nitric oxide synthase, brain (NOS1) |
active in vivo (10 mg/kg) |
(80) |
| memantine |
metabotropic glutamate receptor 2 (GRM2) |
active/100 μM |
(81) |
| memantine |
glycogen synthase kinase-3 beta (GSK3B) |
inhibit GSK-3/100 μM |
(82) |
